GlassScriptPhysician profile
Ricardo Alberto Pollitt
NPI 1578889911
$7,895.65
in general payments reported to CMS, 2019-2025
24 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $344 · 2021: $772 · 2022: $1,167 · 2023: $1,899 · 2024: $1,593 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,626 · Education: $414 · Grant: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,625.76 |
| Education | $413.77 |
| Grant | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,594.92 | 2019-2025 | |
| Leo Pharma INC. | $1,032.54 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $1,031.85 | 2019-2025 | |
| Janssen Biotech, INC. | $575.48 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $449.24 | 2022-2024 | Sotyktu, Reyataz |
| Dermavant Sciences, INC. | $286.33 | 2023-2024 | Vtama |
| Incyte Corporation | $284.07 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $248.76 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $241.28 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $186.49 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $181.69 | 2019-2025 | Aklief, Nemluvio |
| Ucb, INC. | $171.29 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $129.21 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $92.80 | 2021-2025 | |
| Amgen INC. | $86.45 | 2023-2025 | Otezla, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Arcutis Biotherapeutics, INC. | $71.60 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $36.71 | 2020 | |
| Vyne Pharmaceuticals INC. | $28.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.98 | 2024 | Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.58 | 2019 | |
| Genentech USA, INC. | $15.38 | 2019 | |
| Organon LLC | $15.14 | 2025 | Vtama |
| Mylan Pharmaceuticals INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Pollitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.